CoChat

Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805

Baffert, Fabienne, Régnier, Catherine H., De Pover, Alain, Pissot-Soldermann, Carole, Tavares, Gisele A., Blasco, Francesca, Brueggen, Josef, Chène, Patrick, Drueckes, Peter, Erdmann, Dirk, Furet, Pascal, Gerspacher, Marc, Lang, Marc, Ledieu, David, Nolan, Lynda, Ruetz, Stephan, Trappe, Joerg, Vangrevelinghe, Eric, Wartmann, Markus, Wyder, Lorenza, Hofmann, Francesco, Radimerski, Thomas · 2010 · Molecular Cancer Therapeutics
Cited by 120

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

The recent discovery of an acquired activating point mutation in JAK2, substituting valine at amino acid position 617 for phenylalanine, has greatly improved our understanding of the molecular mechanism underlying chronic myeloproliferative neoplasms. Strikingly, the JAK2V617F mutation is found in nearly all patients suffering from polycythemia vera and in roughly every second patient suffering from essential thrombocythemia and primary myelofibrosis. Thus, JAK2 represents a promising target for the treatment of myeloproliferative neoplasms and considerable efforts are ongoing to discover and develop inhibitors of the kinase. Here, we report potent inhibition of JAK2V617F and JAK2 wild-type enzymes by a novel substituted quinoxaline, NVP-BSK805, which acts in an ATP-competitive manner. Within the JAK family, NVP-BSK805 displays more than 20-fold selectivity towards JAK2 in vitro, as well as excellent selectivity in broader kinase profiling. The compound blunts constitutive STAT5 phosphorylation in JAK2V617F-bearing cells, with concomitant suppression of cell proliferation and induction of apoptosis. In vivo, NVP-BSK805 exhibited good oral bioavailability and a long half-life. The inhibitor was efficacious in suppressing leukemic cell spreading and splenomegaly in a Ba/F3 JAK2V617F cell-driven mouse mechanistic model. Furthermore, NVP-BSK805 potently suppressed recombinant human erythropoietin-induced polycythemia and extramedullary erythropoiesis in mice and rats. Mol Cancer Ther; 9(7); 1945–55. ©2010 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-10-0053

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 120

Metadata

Authors
Baffert, F., Régnier, C. H., De Pover, A., Pissot-Soldermann, C., Tavares, G. A., Blasco, F., Brueggen, J., Chène, P., Drueckes, P., Erdmann, D., Furet, P., Gerspacher, M., Lang, M., Ledieu, D., Nolan, L., Ruetz, S., Trappe, J., Vangrevelinghe, E., Wartmann, M., Wyder, L., Hofmann, F., & Radimerski, T.
Venue
Molecular Cancer Therapeutics
Published
2010-07-01
Volume
9
Issue
7
Pages
1945-1955
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2130062751
Cited by
120
References
3
FWCI
4.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805. https://app.cochat.ai/papers/10.1158/1535-7163.mct-10-0053
The paper
Baffert, F., Régnier, C. H., De Pover, A., Pissot-Soldermann, C., Tavares, G. A., Blasco, F., Brueggen, J., Chène, P., Drueckes, P., Erdmann, D., Furet, P., Gerspacher, M., Lang, M., Ledieu, D., Nolan, L., Ruetz, S., Trappe, J., Vangrevelinghe, E., Wartmann, M., . . . Radimerski, T. (2010). Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-10-0053

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.